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The Human Research Program (HRP):
• NASA program that provides human health and performance 
countermeasures, knowledge, technologies, and tools 
• Enables safe, reliable, and productive human space exploration
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Exploration Medical Capability 
Trade Study Overview
A trade study is a quantitative decision making activity used to identify the 
most acceptable solution amongst a set of proposed solutions.
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obJect1ves and constraints 
• criteria and weights 
alternative against evaluation criteria 
Trade Study Overview
A trade study is a quantitative decision making activity used to identify the 
most acceptable solution amongst a set of proposed solutions.
IEEE Aerospace Conference 
03/11/2020
8
How does a 10% reduction 
of mass and volume affect 
the capabilities of medical
imaging? 
? 
• 
.~ 
. ;) 
Problem Introduction
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NASA is committed to successfully extending human exploration 
beyond Low Earth Orbit. 
9
Deep space will be different…
NASA ExMC’s Need: 
Provide a data-driven means to inform human health and performance risk mitigation 
interests during resource constrained exploration mission development.
Problem Introduction
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Proposed Solution
To facilitate the exploration beyond Low Earth Orbit with constrained 
resources, NASA’s ExMC Element is:
• Utilizing a Model-Based Systems Engineering approach
• Building a tool suite ecosystem to perform trade study analyses
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Question 
Stakehollders POC Tool Suite SMEs 
Recommendations 
Ana lvsis/1 nterp retation 
Tool Suite Overview
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Tool Suite Description – Evidence Library
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Evidence Library
 Condition incidence rates
 Clinical phase durations (how long a condition treatment lasts) 
 Likelihoods of mortality or need to return to definitive care
 Functional impairment
EMSM
Systems Engineering 
Tool
Inputs 
MedlD 
Resource Tool 
PRA 
r 
I 
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Post Processing 
Excel & Tableau 
Post-Processing Tools 
Repeat 
EMSM
Systems Engineering 
Tool
Tool Suite Description – MedID
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Medical Item 
Database (MedID)
Secure, cloud-based database of medical items and resources 
potentially available for spaceflight
Inputs 
Evidence Library 
Medical Evidence 
MedlD 
Resource Tool 
PRA 
r 
I 
I 
Post Processing 
Excel & Tableau 
Post-Processing Tools 
Repeat 
Tool Suite Description – MedID
Selected capabilities of MedID: 
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Medical System Master Equipment List Date Created TOTALS: Total Mass: Total Volume:Total Power:
Trial Run: 38_TI 8/15/2019 kg cm^3 watt
4.8753181 15708.768 400
Resource Initial_QuantityConsumableEssential Mass Volume Power Total_Mass Total_VolumeTotal_Power
kg cm^3 watt kg cm^3 watt
ABILIFY (ARIPIPRAZOLE) 5 MG 0 1 1 0.00013 0.1 0 0 0 0
ABILIFY (ARIPIPRAZOLE) 7.5 MG/ML, 1.3 ML 0 1 1 0.00024 0.2 0 0 0 0
ABSORBABLE SUTURE 3.0 1 1 1 0.0567 46.9 0 0.0567 46.9 0
ACE BANDAGE 2 INCHES 1 0 1 0.02268 31.7 0 0.02268 31.7 0
ACE BANDAGE 3 INCHES 1 0 1 0.03118 42.6 0 0.03118 42.6 0
ACE BANDAGE 4 INCHES 1 0 1 0.04536 51.6 0 0.04536 51.6 0
ADRENALINE (EPINEPHRINE 1:10000) 10ML 1 1 1 0.01 10 0 0.01 10 0
Figures of Merit: Shows the ability to characterize 
and sort resources based on physical characteristics
Master Equipment List: Shows an example snapshot of a 
list of some resources available and their quantities, mass, 
volume, and power
EHHhHM 
•• •• 
ITEM DETAILS 
I 
c~ 
MEASUREMENTS POWER INFORMATION 
• 
MISSION INFORMATION • SOURCE 
.. . 
... 
CHILDREN 
SAVE ITEM DELETE IT!M ADD TO CART 
IIJ FIGURES OF MERIT & ADDITIONAL INFORMATION 
FIGURES OF MERIT 
Development Level 
0 Microgravity Sensttlve 
0 Affected by Radiation 
0 Affected by Himidlly Level 
0 Affected by Pressure 
0 Requires Tliermal Control 
0 Requires Water Source 
0 Requires Vacuum source 
0 R,:qulres Gas (02, N2. etc 
0 Requires Ste~llzallon 
0 Requires VobrelloneRy Quiet 
Emlro ment 
0 RequlresAcoustJcaOv Quiet fnv1ronmert 
0 Requires Ground Commumcatton 
0 eommerctally Available 
0 FDA Approved 
+ + 
+ + 
EMSM
Systems Engineering 
Tool
Tool Suite Description – MEDPRAT 
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Medical Extensible 
Dynamic 
Probabilistic Risk 
Assessment Tool 
(MEDPRAT)
 Determines the most nearly optimal set of medical resources to 
meet target values within acceptable risk thresholds
 Computes risk factors, condition occurrences, and resource 
utilization for a given mission and crew
Inputs PRA Post Processing 
Evidence Library ____ .. ____ Excel & Tableau 
Medical Evidence ~ ---------..... .11111111• Post-Processing Tools 
MedlD 
Resource Tool 
Repeat 
EMSM
Systems Engineering 
Tool
Tool Suite Description – Excel & Tableau
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Excel & Tableau Visualizes pertinent MEDPRAT data in the context of user queries
Inputs 
Evidence Library 
Medical Evidence 
MedlD 
Resource Tool 
PRA 
r 
I 
I 
Post Processing 
Repeat 
Tool Suite Description – Excel & Tableau
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Selected capabilities of the post processing tools:  
LO
C
L
System Characteristics: Shows 
scenario information in a table
Resource Information: Shows the resource data 
by most utilized resource for multiple scenarios
Risk Information: Shows 
the ability to compare risk 
metrics for multiple 
scenarios
0.0009 
0.0008 
Resource Ut i I izat ion 
0.0007 
System Characteristic System 1- Run 1 System 2-Run 2 Resource Name Scenario 
Motrin ( buprofen) 400mg 01 
0.0006 
Mass (kg) 115.2 106.6 05 0.0005 
Prob of Loss of Crew 0.0057 0.0061 BZK wipes 01 
Prob of EVAC 0.0999 0.101 05 0.0004 
Crew Health Index 0.929 0.928 Amoien 10mg tablet 01 
Requirements not met 0 4 05 
Tyle ol {Aceta inophen) 01 
0.0003 
Conditions not addressed 0 32 325mg 05 
A'rin (Oxymetazoline) 01 0.0002. 
0.05~' 15 _ bottle 05 
0.0001.. 
0.0000 
1..7 1..9 
EMSM
Systems Engineering 
Tool
Tool Suite Description – EMSM 
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Exploration 
Medical System 
Model (EMSM)
 Houses the capabilities and requirements of the medical system
 Produces reports of conditions/requirements that are satisfied by a 
candidate set of resources
Inputs PRA Post Processing 
Evidence Library Excel & Tableau 
Medical Evidence ---------- Post-Processing Tools 
MedlD 
Resource Tool 
Repeat 
Tool Suite Description – EMSM  
Selected capabilities of the Exploration Medical System Model: 
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Dependency Matrix: Shows the 
relationship between medical resources and 
conditions
Impacted Medical Condition List: Shows the impact of the
removal of medical resources on condition treatment
capabilities and requirements satisfaction (SysML & Excel)
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) 'm ) Delete RernoveFromM<ltro: f Chani;eAAes lX! Elq)o(t [ Q @.~~0. 80% 
Criterill 
RowElementType: ;=~=·=·~~--------,' 
Row Scope: ~ icnl Conditions ==-::J 
Dependency Criterill: ] Allocllte,Allocllte QnP!ied}__ ~ 
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~-o-~ 
~:g::::=Syndrano 
tg::~(NH,--.) 
tg::;:-
~0.o.l!QN{~I-
~-{} - lo!ip<.;r,/!ilnin 
tg::=_ 
E B -
: 
i 
! 
• 
1111 
'' ... 
. 
' . 
. 
~ 0.o.triol --.,,Atriol~ 
~-{}Bod<- (5po<o,A~) 
~ {}Bod<!ip<ao,/Slr.., 
~-o-....... <-, ..... -i 
~o--~ 10 10 ✓ 
✓✓✓ 
✓ 
tg~~~.,~W-»: 
~i=.:~...._ lD JD 
~g=:-'("'::~ .. - ---- ~ 1~ 
r ~o.,u!Abocm 7 ~U~-
✓ 
Direction: Columntorow 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ ✓ ✓ 
✓ ✓ 
✓ 
✓ 
✓ 
✓ 
✓ 
✓ ✓ 
✓ ✓ 
✓ 
✓ 
Show Elements: 1All 
✓ 
✓✓ 
✓ ✓ ✓ 
✓✓ ✓ ✓ 
✓✓ ✓ ✓ 
✓✓✓ ✓ 
✓✓ ✓ ✓ ✓ 
✓✓ 
✓✓ ✓✓ ✓ 
✓✓ ✓ ✓ 
✓ ✓✓ ✓ 
✓✓ ✓ ✓ 
✓✓ ✓ ✓ 
✓✓ 
✓ ✓ 
✓✓ ✓✓ ✓ 
✓✓ ✓ ✓ 
✓✓ ✓ ✓ 
✓✓ ✓ ✓ 
✓✓ ✓ ✓ 
✓✓ 
• A Name Scenario 19 I terns Scenario 38 Items Mecic:al Conditions Trace Rec,Ji"ements Trace ReSOU"ceType 
1 Q Abiify(A<wazole ... O Beho\lK)(al Emergency [!] Hab-MedSys-ReSOU"ces-0001 Provide Ability (Arwazole) 7.5mg/rr Abiify (Anp,p,azole) 7. 5 mgfrr'-,1.Jn-j_ 
2 i;:JAbsort>ableSubse ... ~ ABSORBABI.E SUTURE 3.0 OSmLaceration [!] Hab-MedSys-Resou-ces-0002 Provide Absorbable Suhxe 3.0 Absorbable Sub.re 3.0 
~ ACE BANDAGE 2 INCHES 0 AOJte Comparbnent Syndrome []) Hab-MedSys-Resc:uces-0003 Provide Ace bandage 2 ndles Ace bandage 2 inches 
0 Shoulder Dislocation 
3 Q Ace bandage 2 nd1es 0 Lower Extremity (LE) Stress FractJ.re 0 Ebowo;slocation 
0 Hip/Proxinal Ferru Ffacb..re 
0 Shoulder Sprain/Strai"l 
~ ACE BANDAGE 3 INCHES 0 EbowOislocation al Hab-MedSys-Resources-0004 Provide Ace banda9e 3 ilches Ace bandage 3 inches 
0 Lower Extremity (LE) Stress Ffadlxe 
0 Shoude,Q;slocation 
0 Wrist SprailfStriWI 
✓ 
i:;J Ace bandage 3 nd1es 
0 Kntt Spra'1/Stra'1 
4 0 Wrist Fracb.re 
0 Hipft'roxmal Fenu Ffactu-e 
✓ 
0 AOJl:t: Compartment Syndrome 
0 Ebow Sprai-1/Strail 
0 Shoude< Spra'1/Stra'1 
... 
~ ACE BAf'IOAGE 4 INOiES 0 Hip/Proxinal F~ Ffachxe [!] Hab-MedSys-ReSOU"ces-0005 Provide Ace bandage 4ndles Ace bandage 4 nches 
0, Wrist Sprail/StrMI 
0 Lower Extremity (LE) Stress Fracb.xe 
5 ~ Ace bandage 4 nches 0 Shouder Sprain/Strain 0 EbowOislocation 
0 Ebow Sprain/Strain 
0 AOJl:t: Compartment Syndrome 
0 Shoude,o;slocation 
i;:J Acl-enme (Ep,neplme 1, ~ ADRENALINE (EPJNEPHUI' 0 Cardic>Qerk Shock secondary to Myocarc C!1 Hab4'1\edSys-Resoll'ces-0006 Provide Adrenaline ~ine 1: lOC Adrenme(Ep,neply,ne 
✓ '1)Sepsis 
1,10000) 10... 
✓ ✓✓✓ ,/,/,/,/ 6 ~ Acl-ena01e (Ep;nep .. 0 Traunatic Hypovolemic Shock 
O Neurogenc Shock 
Lt_ 1w ,., ... 0 Sudden Cardiac Arrest 
Tool Suite Pilot Project
Phase I & Phase II
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Tool Suite Pilot Project Goals
Phase I: 
• Demonstrate the ability for the user to 
interact with the tool suite to produce 
outcomes 
• Medical Equipment List (MEL)
• Risk parameters
• Medical system requirements satisfaction
• Medical conditions addressed
Phase II: 
• Demonstrate the medical system 
optimization
• Show tool and team integration
• Perform more substantial trade analyses
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Tool Suite Pilot Project Scenarios
Trial DRM Medical Capability Trade Scenarios Outcomes
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) A
42 days
4 crew - 1 female
EVAs
ISS medical kit
Remove space motion sickness medications from a baseline 
medical set and determine outcomes 
Removing meds resulted in increases in LOCL, QTL, and RTDC 
B
365 days
6 crew - 1 female
EVAs
ISS medical kit
Remove a significant portion of mass/volume by eliminating 
defibrillator and oxygenation hardware
 Removing equipment resulted in non-significant increases in LOCL, QTL, and 
RTDC 
 32 conditions no longer addressed
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C
42  days
4 crew - 1 female
EVAs
Updated medical set 
from MedID
Investigate effects of:
 Extend mission to 90 days
 With/without EVAs
 With/without RTDC option
 With/without pre-existing conditions among crew members
 Mission duration increase from 42 days to 90 days contributed significantly to 
increased risk
 Other effects did not significantly affect risk factors for a 42 day mission
 High variance in outcomes, especially LOCL
D
42 days
4 crew - 1 female
No EVAs
Optimized version of 
Trial C
 Optimize to meet a mass target only. Reduce baseline 
mass target by 12.5% and 25%.  
 Optimize each combination within acceptable LOCL only, 
then within acceptable QTL only
 Optimizing to meet a mass target for LOCL only resulted in unacceptably high 
QTL
 Optimizing for QTL only still resulted in acceptable LOCL
E
42 days
4 crew - 1 female
No EVAs
Optimized version of 
Trial C
 Optimize to meet a volume target only. Reduce baseline 
volume target by 12.5% and 25%.  
 Optimize each combination within acceptable LOCL only, 
then within acceptable QTL only
 Optimizing to meet a volume target for LOCL only resulted in unacceptably high 
QTL
 Optimizing for QTL only still resulted in acceptable LOCL
F
42 days
4 crew - 1 female
No EVAs
Optimized version of 
Trial C
 Optimize to meet a weighted combination of mass and 
volume targets.  
 Optimize each combination within acceptable LOCL only, 
then within acceptable QTL only
 Optimizing to meet a combined mass and volume target for LOCL only resulted 
in unacceptably high QTL
 Optimizing to meet a combined mass and volume target for QTL only still 
resulted in acceptable LOCL
 Better overall solution when volume weighting was higher relative to mass
G
42 days
4 crew - 1 female
No EVAs
Optimized version of 
Trial C
Optimize to meet mass target or a weighted combination of mass 
and volume targets and a weighted combination of acceptable 
risk thresholds. 
 A weighted combination of risk thresholds resulted in the ability to meet both 
simultaneously
 Better overall solution when volume weighting was higher relative to mass
H
42 days
4 crew - 1 female
No EVAs
Optimized version of 
Trial C
Optimize to meet a mass target with the two heaviest items 
reduced in mass and volume by 80% each through technology 
development
 An 80% reduction in mass of two bulky items permits their inclusion in the 
medical system and enables medical requirements to be met that were 
previously not being met, while maintaining acceptable risk
I
42 days
4 crew - 1 female
No EVAs
Optimized version of 
Trial C
Determine the weighting coefficients required to meet mass and 
volume targets as well as acceptable thresholds for LOCL and 
QTL simultaneously. 
 It was possible to meet mass and volume targets within acceptable risk 
thresholds for LOCL and QTL
 The target for volume requires a higher weighting because it constrains the 
medical system more than the target for mass
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Tool Suite Pilot Project Success Criteria
Phase I: 
Given a Design Reference Mission, 
produce the following outputs: 
• Medical Equipment List (MEL)
• Risk parameters
• Medical system requirements satisfaction
• Representative medical conditions 
addressed
Ensure consistent data products 
across tools and team
Produce results quickly
Document lessons learned
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Tool Suite Pilot Project Success Criteria
Phase I: 
Given a Design Reference Mission, 
produce the following outputs: 
• Medical Equipment List (MEL)
• Risk parameters
• Medical system requirements satisfaction
• Representative medical conditions 
addressed
Ensure consistent data products 
across tools and team
Produce results quickly
Document lessons learned
Phase II: 
Demonstrate the effectiveness of new
features and enhancements to the 
tool suite
• Optimization
• Requirements and conditions in EMSM
Integrate the tools better into a well-
functioning whole
Develop post-processing tools that 
facilitate efficient and effective 
interpretation of results from the tool 
suite
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Significant Findings of Pilot Project Phase II
Post-processing in Tableau makes it easy to determine information about: 
• Conditions
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42 days
90 days
Condi . ion 01ccurrences ... 
Corn dition Na me 
S - D SOPDE 
-
-• 
SP E OT NS C N: 
( P· CE . ION 
--------------,--
N S L 
( P· CE 
Significant Findings of Pilot Project Phase II
Post-processing in Tableau makes it easy to determine information about: 
• Conditions
• Risks
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42 days
90 daysCon 1ditions lnflue,ncing QTL 
Condiilt ion Sree111ario 
V ISUAL IM PAIRMENT A__ 01 
05 
SKIN RASH 01 
05 
SKI AB AS I ON 01. 
05 
NECK SPRAIN/ STRAIN 01 
05 
EYE IRRITATION/ AB ASL_ 01 
05 
SPAC E MOT ION SIC KN ES __ 01 
05 
SLEEP DISORDER 01 
05 
I 
-0 .1 2 3 4 5 6 7 
Significant Findings of Pilot Project Phase II
Post-processing in Tableau makes it easy to determine information about: 
• Conditions
• Risks
• Resources
IEEE Aerospace Conference 
03/11/2020
30
42 days
90 daysResource Util i·zation 
Resource Name -:- Scenar1io 
M rin ( bu rofen) 
B Kwi es 
m ien 10rr a let 
T yle ol ( cet- in phen) 
· g 
Summary of Results
• The tool suite is providing results that meet clinician face validation based 
on the input conditions and assumptions
• The tools are working together well, with opportunities for further integration 
and automation
• We have identified the process necessary for using the tools to achieve 
results for some very specific and useful types of trades
• Technology Development
• Medical set optimization and fine tuning
• Pilot projects phase I and II have fully met the success criteria
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Summary of Results
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For any given mission with defined number/gender of crew, pre-existing 
conditions, mission duration, extra-vehicular activity, and starting medical 
capabilities, the tool suite can: 
 Identify a nearly optimal set of medical resources
 Identify system requirements and requirement satisfaction
 Identify medical conditions that will occur
 Identify medical capabilities that will be met/unmet
 Meet all notional targets
 Meet all notional constraints
Analysis Results: Trial B Run1 Trial B Run 2
1. Number of requirements missing 
from the trial run compared to the 
generic list: 0 4
Trial B Run 1 Missing Requirements:
Trial B Run 2 Missing Requirements: Provide AED 
Provide Blood Oximeter 
Provide Variable Oxygen 
System 
Provide VOS Intubated Patient 
Hardware 
(Ventilator/Respirator) 
Baseline Mission, no EVAs
Extended Mission, with EVAs
LOCL QTL
Condit ion I fl 
. . s n uencing LOCL 
Cond1t1on 
SEPSIS 
Scenario 
17 
SMOKE INHALATION 
TRAUMATIC HYPOVOLE 
ACUTE DIVERTICU LITIS .. 
APPENDICITIS 
17 
17 
17 
17 
Risks fo S r cena r io 0 1 & 1 6 
0.0017 
0.0016 
0.0015 
0.0014 
0.0013 
0.0012 
00003 
0.0002 
0.0001 
0.0000 
See nario 
• 01 
16 
01 16 
15 
I 14 
13 
12 
11 
, 4 
3 
1: 
0 
01 16 
Significance
• Identify which medical capabilities have the potential to provide the greatest
possible risk reduction benefit, leading to an increased likelihood of their
inclusion in exploration medical systems.
• Can inform NASA mission developers regarding the prioritization of
research and technology development for deep space medical capability.
• Enables human health and performance to be considered as early as
possible in the mission planning and vehicle design process, allowing for full
integration into architectures as they are conceptualized, developed, and
adopted.
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Limitations of Work
• Limitations of the individual tools
• Folder structures were inconsistent
• Learning curve for the tools 
• Geographically distributed team
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Evidence 
Library
Updates to condition incidence rates used by MEDPRAT, updates to 
conditions to consider, and updates to treatment and resource capabilities are 
in process.
MedID
The ServiceNow platform used in Phase II was not as configurable as 
previously expected. The team is moving towards using an SQL database.
MEDPRAT The capability to capture condition interdependencies is in development.
Excel & 
Tableau
The stakeholders need to have the appropriate software to view results.
EMSM
The requirements set is still in development, resulting in incomplete tracing 
among all applicable requirements.
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Future Work
• Technology assessments of candidate components 
• Medical component characteristics to be incorporated
• Automation of data exchange and operation, including integration scripts
• Development of evidence base and models for MEDPRAT
• Bundling resources together using resource dependencies
• Simulation of longer duration missions with potential new capabilities
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Thank you! 
Questions? 
Please contact us! 
Jennifer Amador – jennifer.r.amador@nasa.gov
William Thompson – william.k.thompson@nasa.gov
Jennifer Mindock – jennifer.a.mindock@nasa.gov
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Backup Slides
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Trade Study Overview
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I want to go out to 
eat for dinner.
Trade Study Overview
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The restaurant must be less 
than 10 miles from my location, 
have good food, and be 
reasonably priced.
Distance: 1 (least important)
Food Quality: 3 (most important) 
Price: 2 
Trade Study Overview
IEEE Aerospace Conference 
03/11/2020
40
1) Fast Food 
2) Local Restaurant
3) Banquet Hall
Trade Study Overview
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1) Fast food: .5 miles away 
with low quality food, very 
cheap.
2) Local restaurant: 12 miles 
away with good quality 
food, moderately priced.
3) Banquet hall: 7 miles away 
with moderate quality food, 
very expensive. 
Trade Study Overview
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Distance 
(1)
Food 
Quality 
(3)
Price 
(2)
Total
Score
Fast Food 3 1 3 12
Local 
Restaurant
2 3 2 15
Banquet 
Hall
1 2 1 9
Trade Study Overview
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Distance 
(1)
Food 
Quality 
(3)
Price 
(2)
Total
Score
Fast Food 3 1 3 12
Local 
Restaurant
2 3 2 15
Banquet 
Hall
1 2 1 9
Trade Study Overview
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This information needs 
to be accessible so that 
I can make this same 
decision again next 
week with different 
restaurants!
Potential Stakeholders of the Tool Suite
IEEE Aerospace Conference 
03/11/2020
Potential Stakeholders Life Cycle Phase Scenario
OCHMO, MedOps Pre-Phase A Condition likelihoods with level of care 
definitions
Exploration Program Systems Engineering 
Team
Pre-Phase A Mass and volume allocation
ExMC Leadership Pre-Phase A Research prioritization
HRP Elements Pre-Phase A Risk assessment
Mars Program CHP System Management Phase A Requirements development
Exploration Program CHP System 
Management, Exploration Program 
Management
Phases B/C Trade analysis to identify system 
resources
Mars Program Management, MedOps Phase D Updated risk impact just prior to 
mission
MedOps, OCHMO, Lunar Program 
Management, Lunar Program Medical System 
Management
Phase E Updated risk impact if new condition 
occurs, using real-time inventory
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